Amara J F, Dannies P S
Mol Cell Endocrinol. 1986 Oct;47(3):183-9. doi: 10.1016/0303-7207(86)90111-5.
The antiestrogens LY117018 and tamoxifen increased prolactin production about 4-fold and cell number about 2.5-fold in the pituitary tumor cell line, GH4C1; these increases were 30-40% of the maximal effects of estradiol. The antiestrogens competed with binding of [3H]estradiol, and LY117018 was more active than tamoxifen in biological activities and binding activity. The antiestrogens inhibited stimulation caused by 10(-10) M estradiol; the inhibition could be overcome by increased estradiol concentrations. Tamoxifen and LY117018 increased the amount of prolactin mRNA per cell. These antiestrogens behave as partial agonists in the GH4C1 cells, but have two unusual features. Estrogens are approximately 10-fold more potent in stimulating cell number than in stimulating prolactin production, but the antiestrogens showed the same dose-response for both effects. The partial agonist activity was biphasic and at higher concentrations the antiestrogens showed more antagonist activity (GH4C1 cells, 17 beta-estradiol, tamoxifen).
抗雌激素药物LY117018和他莫昔芬可使垂体肿瘤细胞系GH4C1中的催乳素分泌增加约4倍,细胞数量增加约2.5倍;这些增加量为雌二醇最大效应的30%-40%。抗雌激素药物可与[3H]雌二醇的结合发生竞争,且LY117018在生物活性和结合活性方面比他莫昔芬更具活性。抗雌激素药物可抑制由10(-10)M雌二醇引起的刺激作用;增加雌二醇浓度可克服这种抑制作用。他莫昔芬和LY117018可增加每个细胞中催乳素mRNA的量。这些抗雌激素药物在GH4C1细胞中表现为部分激动剂,但有两个不寻常的特征。雌激素在刺激细胞数量方面的效力比刺激催乳素分泌约强10倍,但抗雌激素药物对这两种效应表现出相同的剂量反应。部分激动剂活性呈双相性,在较高浓度下抗雌激素药物表现出更多的拮抗剂活性(GH4C1细胞、17β-雌二醇、他莫昔芬)。